Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan.
Extended-spectrum beta-lactamases, plasmid-mediated AmpC beta-lactamases (PABLs), and plasmid-mediated metallo-beta-lactamases confer resistance to many beta-lactams. In Japan, although several reports exist on the prevalence of extended-spectrum beta-lactamases and metallo-beta-lactamases, the prevalence and characteristics of PABLs remain unknown. To investigate the production of PABLs, a total of 22,869 strains of 4 enterobacterial species, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Proteus mirabilis, were collected during six 6-month periods from 17 clinical laboratories in the Kinki region of Japan. PABLs were detected in 29 (0.13%) of 22,869 isolates by the 3-dimensional test, PCR analysis, and DNA sequencing analysis. PABL-positive isolates were detected among isolates from 13 laboratories. Seventeen of 13,995 (0.12%) E. coli isolates, 8 of 5,970 (0.13%) K. pneumoniae isolates, 3 of 1,722 (0.17%) K. oxytoca isolates, and 1 of 1,182 (0.08%) P. mirabilis isolates were positive for PABLs. Of these 29 PABL-positive strains, 20 (69.0%), 6 (20.7%), 2 (6.9%), and 1 (3.4%) carried the genes for CMY-2, DHA-1, CMY-8, and MOX-1 PABLs, respectively. Pattern analysis of randomly amplified polymorphic DNA and pulsed-field gel electrophoretic analysis revealed that the prevalence of CMY-2-producing E. coli strains was not due to epidemic strains and that 3 DHA-1-producing K. pneumoniae strains were identical, suggesting their clonal relatedness. In conclusion, the DHA-1 PABLs were predominantly present in K. pneumoniae strains, but CMY-2 PABLs were predominantly present in E. coli strains. The present findings will provide significant information to assist in preventing the emergence and further spread of PABL-producing bacteria.
Yamasaki
Katsutoshi
K
Department of Clinical Laboratory, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama City, Wakayama 640-8505, Japan. ktt-yamazaki@wakayamah.rofuku.go.jp
Komatsu
Masaru
M
Abe
Noriyuki
N
Fukuda
Saori
S
Miyamoto
Yugo
Y
Higuchi
Takeshi
T
Ono
Tamotsu
T
Nishio
Hisaaki
H
Sueyoshi
Noriyuki
N
Kida
Kaneyuki
K
Satoh
Kaori
K
Toyokawa
Masahiro
M
Nishi
Isao
I
Sakamoto
Masako
M
Akagi
Masahiro
M
Nakai
Isako
I
Kofuku
Tomomi
T
Orita
Tamaki
T
Wada
Yasunao
Y
Jikimoto
Takumi
T
Kinoshita
Shohiro
S
Miyamoto
Kazuaki
K
Hirai
Itaru
I
Yamamoto
Yoshimasa
Y
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000096:biosynthesis* / Q000235:genetics*; D015373:Bacterial Typing Techniques; D016172:DNA Fingerprinting; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D016521:Electrophoresis, Gel, Pulsed-Field; D004756:Enterobacteriaceae Infections / Q000382:microbiology*; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007564:Japan; D007709:Klebsiella / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D017720:Molecular Epidemiology; D010957:Plasmids / Q000032:analysis*; D016133:Polymerase Chain Reaction; D011513:Proteus mirabilis / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics / Q000302:isolation & purification; D019105:Random Amplified Polymorphic DNA Technique; D017422:Sequence Analysis, DNA; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000235:genetics*; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D047090:beta-Lactams; C048795:AmpC beta-lactamases; D001618:beta-Lactamases